Biobijou바이오비쥬
489460 · KOSDAQ · ₩489460 · 바이오비쥬
₩13,170▼ ₩230 (1.72%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | ₩9.9B | ₩8B | ₩4B | ₩6.6B |
| Cost of sales | ₩5.8B | ₩2.5B | ₩2.2B | ₩2B |
| Gross profit | ₩4.1B | ₩5.5B | ₩1.8B | ₩4.6B |
| Operating income | ₩2.7B | ₩2.6B | −₩2.7B | ₩2.4B |
| Net income | ₩2.5B | ₩2.9B | ₩1.7B | ₩1.9B |
| Net income to shareholders | ₩2.5B | ₩2.9B | −₩1.4B | ₩2.4B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | |
|---|---|---|---|---|
| Total assets | — | ₩68B | ₩64B | ₩67B |
| Current assets | — | ₩52B | ₩48B | ₩54B |
| Cash and equivalents | — | ₩909M | ₩12B | ₩11B |
| Total liabilities | — | ₩4.3B | ₩1.8B | ₩3B |
| Current liabilities | — | ₩4.2B | ₩1.6B | ₩2.8B |
| Borrowings | — | ₩0 | ₩0 | — |
| Total equity | — | ₩63B | ₩62B | ₩64B |
| Shareholders' equity | — | ₩63B | ₩62B | ₩64B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | |
|---|---|---|---|---|
| Cash from operations | ₩1.2B | ₩5.8B | −₩4B | −₩2.6B |
| Capital spending | ₩59M | ₩44M | ₩112M | ₩101M |
| Free cash flow | ₩1.1B | ₩5.8B | −₩4.1B | −₩2.7B |
| Dividends paid | ₩3B | −₩1.5B | — | — |
Consolidated where available. Amounts in won.
Also known as: Biobijou / 바이오비쥬 / 489460 / KRX:489460
Source: KRX statistical information